Suppr超能文献

2型糖尿病与甲状腺癌之间的关联。

The Association between Type 2 Diabetes Mellitus and Thyroid Cancer.

作者信息

Seo Young-Gyun, Choi Ho-Chun, An Ah Reum, Park Do Joon, Park Young Joo, Lee Kyu Eun, Park Sue K, Hwang Yunji, Cho Belong

机构信息

Department of Family Medicine, Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do 14068, Republic of Korea.

Department of Family Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul 03080, Republic of Korea.

出版信息

J Diabetes Res. 2017;2017:5850879. doi: 10.1155/2017/5850879. Epub 2017 Jul 9.

Abstract

AIM

The incidence of thyroid cancer is increasing worldwide. The prevalence of type 2 diabetes mellitus (T2DM) is also increasing. Therefore, we aimed to analyze the effect of T2DM on thyroid cancer.

METHODS

A case-control study was performed. A total of 415 healthy controls with thyroid ultrasound screening and physician consultation were selected from the Thyroid Cancer Longitudinal Study (T-CALOS). Among patients with thyroid cancer who were enrolled in T-CALOS, 415 patients were matched to the control group according to age and sex. We assessed the effects of T2DM, T2DM duration, and T2DM medication on thyroid cancer.

RESULTS

Women with T2DM had lower odds of thyroid cancer than women without T2DM (odds ratio [OR]: 0.40, 95% confidence interval [CI]: 0.20-0.81). Individuals receiving T2DM medication had higher odds of thyroid cancer compared to those without T2DM medication (OR: 5.21, 95% CI: 1.58-17.15). Individuals with T2DM duration <6 years had lower odds of thyroid cancer compared to those without T2DM (OR: 0.58, 95% CI: 0.34-0.97).

CONCLUSIONS

Individuals with early T2DM are presumed to have a low incidence of thyroid cancer, and this effect seems to last up to 6 years after diagnosis of T2DM.

摘要

目的

甲状腺癌的发病率在全球范围内呈上升趋势。2型糖尿病(T2DM)的患病率也在增加。因此,我们旨在分析T2DM对甲状腺癌的影响。

方法

进行了一项病例对照研究。从甲状腺癌纵向研究(T-CALOS)中选取了415名经过甲状腺超声筛查和医生会诊的健康对照者。在纳入T-CALOS的甲状腺癌患者中,根据年龄和性别将415名患者与对照组进行匹配。我们评估了T2DM、T2DM病程和T2DM药物治疗对甲状腺癌的影响。

结果

患有T2DM的女性患甲状腺癌的几率低于未患T2DM的女性(优势比[OR]:0.40,95%置信区间[CI]:0.20 - 0.81)。与未服用T2DM药物的个体相比,服用T2DM药物的个体患甲状腺癌的几率更高(OR:5.21,95% CI:1.58 - 17.15)。T2DM病程<6年的个体患甲状腺癌的几率低于未患T2DM的个体(OR:0.58,95% CI:0.34 - 0.97)。

结论

早期T2DM患者的甲状腺癌发病率较低,且这种影响在T2DM诊断后似乎可持续长达6年。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80f5/5523441/b2f4741c9e8e/JDR2017-5850879.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验